Optimal selection of natural killer cells to kill myeloma: The role of HLA-E and NKG2A

Cancer Immunology, Immunotherapy

Volumn 64, Issue 8, 2015, Pages 951-963

  Sarkar, Subhashis ^a   van Gelder, Michel ^a   Noort, Willy ^b,d   Xu, Yunping ^a   Rouschop, Kasper M A ^c   Groen, Richard ^b,d   Schouten, Harry C ^a   Tilanus, Marcel G J ^a   Germeraad, Wilfred T V ^a   Martens, Anton C M ^b,d   Bos, Gerard M J ^a   Wieten, Lotte ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HLA; Immunotherapy; KIR; Multiple myeloma; NK cell; NKG2A

Indexed keywords

HLA ANTIGEN CLASS 1; HLA E ANTIGEN; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; NATURAL KILLER CELL RECEPTOR NKG2A; DNA BINDING PROTEIN; HLA-E ANTIGEN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY C; OXYGEN; V(D)J RECOMBINATION ACTIVATING PROTEIN 2;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CELL SELECTION; CELL SURFACE; CELL THERAPY; COCULTURE; CONTROLLED STUDY; DEGRANULATION; HUMAN; HUMAN CELL; MOUSE; MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; CELL SEPARATION; CYTOTOXICITY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; METABOLISM; MULTIPLE MYELOMA; PROCEDURES; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; CELL DEGRANULATION; CELL LINE, TUMOR; CELL SEPARATION; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DNA-BINDING PROTEINS; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; MICE; MICE, KNOCKOUT; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; OXYGEN;

EID: 84937977250     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1694-4     Document Type: Article

References (52)

1. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046–1060
2. Kroger N, Shaw B, Iacobelli S et al (2005) Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 129:631–643. doi:10.1111/j.1365-2141.2005.05513.x
3. Shimoni A, Hardan I, Ayuk F et al (2010) Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. Cancer 116:3621–3630
4. El-Cheikh J, Crocchiolo R, Furst S et al (2013) Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. Am J Hematol 88:370–374
5. Koehne G, Giralt S (2012) Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care. Curr Opin Oncol 24:720–726
6. Moreau P (2012) Death of frontline allo-SCT in myeloma. Blood 119:6178–6179
7. Palmer JM, Rajasekaran K, Thakar MS, Malarkannan S (2013) Clinical relevance of natural killer cells following hematopoietic stem cell transplantation. J Cancer 4:25–35
8. Vivier E, Ugolini S (2011) Natural killer cells: from basic research to treatments. Front Immunol 2:18
9. Vivier E, Ugolini S, Blaise D et al (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12:239–252
10. Colonna M, Borsellino G, Falco M et al (1993) HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci USA. 90:12000–12004
11. Parham P (2005) MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5:201–214
12. Braud VM, Allan DS, O’Callaghan CA et al (1998) HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391:795–799
13. Moretta L, Locatelli F, Pende D et al (2011) Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 117:764–771
14. Ruggeri L, Mancusi A, Capanni M et al (2007) Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110:433–440
15. Ruggeri L, Capanni M, Urbani E et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097–2100. doi:10.1126/science.1068440
16. Shi J, Tricot G, Szmania S et al (2008) Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 143:641–653. doi:10.1111/j.1365-2141.2008.07340.x
17. Sutlu T, Alici E (2009) Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Int Med 266:154–181
18. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057
19. Bachanova V, Burns LJ, McKenna DH et al (2010) Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 59:1739–1744
20. Ren XB, Yu JP, Cao S et al (2007) Antitumor effect of large doses IL-2-activated HLA haploidentical peripheral blood stem cells on refractory metastatic solid tumor treatment. Cancer Biother Radiopharm 22:223–234
21. Costello RT, Boehrer A, Sanchez C et al (2013) Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy. Immunology 139:338–341
22. von Lilienfeld-Toal M, Frank S, Leyendecker C et al (2010) Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immunother 59:829–839
23. Fauriat C, Mallet F, Olive D, Costello RT (2006) Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 20:732–733. doi:10.1038/sj.leu.2404096
24. Sarkar S, Germeraad WT, Rouschop KM et al (2013) Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS One 8:e64835. doi:10.1371/journal.pone.0064835
25. Benson DM Jr, Bakan CE, Mishra A et al (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116:2286–2294
26. Frassanito MA, Silvestris F, Cafforio P et al (1997) IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity. Int J Clin Lab Res 27:48–54
27. Nielsen H, Nielsen HJ, Tvede N et al (1991) Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors. Apmis 99:340–346
28. Bernal M, Garrido P, Jimenez P et al (2009) Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum Immunol 70:854–857
29. Carbone E, Neri P, Mesuraca M et al (2005) HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105:251–258. doi:10.1182/blood-2004-04-1422
30. Frohn C, Hoppner M, Schlenke P et al (2002) Anti-myeloma activity of natural killer lymphocytes. Br J Haematol 119:660–664
31. Fauriat C, Andersson S, Bjorklund AT et al (2008) Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. J Immunol 181:6010–6019
32. Godal R, Bachanova V, Gleason M et al (2010) Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant 16:612–621
33. Lehmann D, Spanholtz J, Osl M et al (2012) Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells. Stem Cells Dev 21:2926–2938
34. Berg M, Lundqvist A, McCoy P Jr et al (2009) Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 11:341–355
35. Knorr DA, Ni Z, Hermanson D et al (2013) Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Trans Med 2:274–283
36. Maier S, Grzeschik M, Weiss EH, Ulbrecht M (2000) Implications of HLA-E allele expression and different HLA-E ligand diversity for the regulation of NK cells. Hum Immunol 61:1059–1065
37. Rozemuller H, van der Spek E, Bogers-Boer LH et al (2008) A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. Haematologica 93:1049–1057
38. Alter G, Malenfant JM, Altfeld M (2004) CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294:15–22
39. Alici E, Sutlu T, Bjorkstrand B et al (2008) Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 111:3155–3162
40. Spanholtz J, Preijers F, Tordoir M et al (2011) Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One 6:e20740
41. Martin SK, Diamond P, Gronthos S, Peet DJ, Zannettino AC (2011) The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 25:1533–1542
42. Palmisano GL, Contardi E, Morabito A et al (2005) HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum Immunol 66:1–12
43. Marin R, Ruiz-Cabello F, Pedrinaci S et al (2003) Analysis of HLA-E expression in human tumors. Immunogenetics 54:767–775
44. Lo Monaco E, Tremante E, Cerboni C et al (2011) Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia 13:822–830
45. Wieten L, Mahaweni NM, Voorter CE, Bos GM, Tilanus MG (2014) Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. Tissue Antigen 84:523–535. doi:10.1111/tan.12478
46. Lubeck MD, Steplewski Z, Baglia F et al (1985) The interaction of murine IgG subclass proteins with human monocyte Fc receptors. J Immunol 135:1299–1304
47. Shi J, Tricot GJ, Garg TK et al (2008) Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 111:1309–1317
48. Benson DM Jr, Bakan CE, Zhang S et al (2011) IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 118:6387–6391
49. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A (2012) Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med 209:2351–2365
50. Romee R, Schneider SE, Leong JW et al (2012) Cytokine activation induces human memory-like NK cells. Blood 120:4751–4760
51. El-Sherbiny YM, Meade JL, Holmes TD et al (2007) The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 67:8444–8449. doi:10.1158/0008-5472.CAN-06-4230
52. Fionda C, Soriani A, Malgarini G et al (2009) Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J Immunol 183:4385–4394. doi:10.4049/jimmunol.0901797